OraSure Technologies, Inc. Q3 2025 Earnings Recap

OSUR Q3 2025 November 6, 2025

Get alerts when OSUR reports next quarter

OraSure Technologies reported Q3 2025 total revenues of $27.1 million, reflecting a strategic repositioning amid mixed market conditions, while also highlighting a significant acquisition aimed at expanding their diagnostic portfolio.

Earnings Per Share Beat

$-0.13 vs $-0.16 est.

+18.8% surprise

Revenue Beat

27085000 vs 26443360 est.

+2.4% surprise

Market Reaction

1-Day +0.0%

5-Day -5.0%

30-Day +2.92%

See OSUR alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue for Q3 2025 was $27.1 million, driven by Diagnostics revenues of $14.5 million and Sample Management revenues of $10.3 million.
The company signed a definitive agreement to acquire BioMedomics, adding a rapid test for sickle cell disease to its international diagnostic portfolio.
U.S. Diagnostics revenue anticipated to decline slightly, while International Diagnostics expected to see a 20% year-over-year reduction, reflecting funding challenges in public health.
The renewal of the "Together Take Me Home" program aims to further support HIV self-testing initiatives, contributing an expected $1.8 million in revenue for Q4.
Confidence remains for 2026 growth, particularly in Sample Management, driven by advancements in genomics and increased adoption in international markets.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit OSUR on AllInvestView.

Next Q1 2026